Precision T1D Platform: finerenone or sotagliflozin for cardio-renal risk
Not-yet-recruiting US Phase 2 platform matching adults with long-standing T1D and early kidney or heart-risk markers to finerenone or sotagliflozin. It is a T1D complication study, not a Type 2 trial, and neither drug is approved here as a T1D cardio-renal treatment.
Primary endpoints
- Percent change in UACR from baseline to week 26
- Percent change in NT-proBNP from baseline to week 26
- Incidence of treatment-emergent adverse events over 26 weeks
Results so far
No results. Not yet recruiting; estimated n=57; estimated start 1 November 2026; estimated primary completion 31 December 2029. Last registry update 10 August 2026. Sites listed in Portland and Ann Arbor. Type 2 diabetes is an exclusion; this record is not scored on Type 2 evidence.
The full picture
This platform asks whether people with T1D and early kidney or heart-risk markers can be matched to an existing drug by endophenotype. Finerenone’s T1D kidney evidence remains FINE-ONE; sotagliflozin here is the US heart-failure brand Inpefa, not a Type 1 licence. A registered protocol is not a result, and Priority Review of finerenone is not an approval.